Form 4: Behbahani Ali reports acquisition/exercise transactions in SGP

Rhea-AI Filing Summary

Behbahani Ali reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Behbahani Ali

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	27,400	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 27,400 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behbahani Ali

(Last) (First) (Middle)

2855 SAND HILL ROAD

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		27,400		(1)	02/05/2036	Common Stock	27,400	$0	27,400	D

Explanation of Responses:

1. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.

	/s/ Zachary Bambach, attorney-in-fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ali Behbahani report at SpyGlass Pharma (SGP)?

Ali Behbahani reported receiving a grant of stock options for 27,400 shares of SpyGlass Pharma common stock. The options were granted on February 5, 2026, under the 2026 Equity Incentive Plan and are held as direct beneficial ownership.

What are the key terms of Ali Behbahani’s 27,400 SpyGlass Pharma (SGP) options?

The options give Behbahani the right to buy 27,400 SpyGlass Pharma shares at an exercise price of $16 per share. They expire on February 5, 2036 and were granted as a stock option award classified as a derivative security.

How do Ali Behbahani’s SpyGlass Pharma (SGP) options vest?

The 27,400 options vest monthly in equal installments over time. One thirty-sixth of the shares vests each month after the February 5, 2026 grant date, conditioned on Behbahani’s continued service as an Outside Director through each vesting date.

What role does Ali Behbahani hold at SpyGlass Pharma (SGP)?

Ali Behbahani is identified as both a director and a 10% owner of SpyGlass Pharma, Inc. This dual status is disclosed in the filing and relates to his reporting obligations for stock option grants and other equity transactions with the company.

When do Ali Behbahani’s SpyGlass Pharma (SGP) stock options expire?

Behbahani’s stock options expire on February 5, 2036, giving him a long exercise window. The options remain subject to monthly vesting requirements and his continued status as an Outside Director under the 2026 Equity Incentive Plan.

How many SpyGlass Pharma (SGP) derivative securities does Ali Behbahani hold after this grant?

Following this grant, Behbahani beneficially owns 27,400 derivative securities in the form of stock options. These options are reported as directly owned and correspond to 27,400 underlying shares of SpyGlass Pharma common stock.